1-9 of 9
Steven Novick
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Trial in Progress: First Report of the Phase 1/2 Study of the Safety and Efficacy of CPO107, a Bispecific Agent Targeting CD20/CD47 in CD20 Expressing Non-Hodgkin Lymphoma (NHL)

Free
Alan P. Skarbnik, Franklin L. Chen, Luke Mountjoy, Zaw Win Myint, Patricia A. Young, Andrew R. Whiteley, Steven Novick, Jennifer Su, Qingxi Wang, Kevin Romanko, Xi-De Wang, Yejia Li, Shulin Zhong, Liping Song, Ranjana H. Advani
Journal: Blood
Blood (2022) 140 (Supplement 1): 12059–12060.
https://doi.org/10.1182/blood-2022-164746
Published: 2022
Journal Articles

KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma

Free
Michel Delforge, MDPhD, Rachid C. Baz, MD, Michele Cavo, Natalie S. Callander, MD, Armin Ghobadi, MD, Paula Rodriguez-Otero, MD PhD, María-Victoria Mateos, MD PhD, Monica Massaro, MPH, Li Ding, Payal Patel, Gianfranco Pittari, MD PhD, Steven Novick, MDPhD, Sergio A. Giralt, MD, Jesus G. Berdeja, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–25.
https://doi.org/10.1182/blood-2020-137156
Published: 2020
Journal Articles

KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma

Free
Saad Z. Usmani, MDMBBS,MBA, Jesus G. Berdeja, MD, Anna Truppel-Hartmann, MD, Marie-Laure Casadebaig, Honeylet Wortman-Vayn, Suresh G. Shelat, PhD, Steven Novick, MDPhD, Nina Shah, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-139009
Published: 2020
Journal Articles

Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,

Free
Philipp D. le Coutre, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Javier Pinilla-Ibarz, MD, PhD, Richard A. Larson, MD, Norbert Gattermann, MD, Oliver G. Ottmann, MD, PhD, Andreas Hochhaus, MD, Jerald P. Radich, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MD, MBBS, Giovanni Martinelli, MD, Dong-Wook Kim, MD, PhD, Susan Branford, PhD, Martin C. Müller, MD, Yaping Shou, MD, PhD, Steven Novick, MD, PhD, Xiaolin Fan, PhD, Jorge E. Cortes, Michele Baccarani, MD, Hagop M. Kantarjian
Journal: Blood
Blood (2011) 118 (21): 3770.
https://doi.org/10.1182/blood.V118.21.3770.3770
Published: 2011
Journal Articles

5-Year Follow-up of Patients with Relapsed/Refractory CLL Treated with Standard Chemotherapy with or without Oblimersen in Randomized Phase III Trial: Prognostic Factors and Predictive Factors for Treatment Effect

Free
Susan O’Brien, M.D., Jane Wu, PhD, Steven Novick, MD, PhD, Kanti R. Rai, MD
Journal: Blood
Blood (2008) 112 (11): 4201.
https://doi.org/10.1182/blood.V112.11.4201.4201
Published: 2008
Journal Articles

Addition of Oblimersen (Bcl-2 Antisense) to Fludarabine/Cyclophosphamide for Relapsed/Refractory Chronic Lymphocytic Leukemia Extends Survival in Patients Who Achieve CR/nPR: Results from a Randomized Phase 3 Study.

Free
Susan O’Brien, Joseph Moore, Lily Ding, Steven Novick, Kanti Rai
Journal: Blood
Blood (2007) 110 (11): 751.
https://doi.org/10.1182/blood.V110.11.751.751
Published: 2007
Journal Articles

Phase 1 Assessment of an Orally Bioavailable Formulation of Gallium Nitrate (G4544).

Free
Thomas Julian, Shingai Majuru, Moses Oyewumi, Steven Novick, Miriam Mangelus, Bob Brown, Bharat Mehta, Raymond P. Warrell, Jr., Lewis H. Bender
Journal: Blood
Blood (2007) 110 (11): 4455.
https://doi.org/10.1182/blood.V110.11.4455.4455
Published: 2007
Journal Articles

Phase 2 Multicenter Trial of Gallium Nitrate in Patients with Advanced Non-Hodgkin’s Lymphoma (NHL).

Free
Barbara Pro, MD, R. G. Bociek, MD, Christopher R. Chitambar, MD, Stephanie A. Gregory, MD, John P. Leonard, MD, Sandra Smith, Steven Novick, MD
Journal: Blood
Blood (2004) 104 (11): 2487.
https://doi.org/10.1182/blood.V104.11.2487.2487
Published: 2004
Journal Articles

A Pilot Study of Genasense® (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

Free
Asher Alban Chanan-Khan, MD, Blanche Mavromatis, MD, Kanti R. Rai, MD, Philomena Casey, Steven Novick, MD, Loretta M. Itri, MD
Journal: Blood
Blood (2004) 104 (11): 4827.
https://doi.org/10.1182/blood.V104.11.4827.4827
Published: 2004